Ponatinib

Overview

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC 50 s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl , PDGFRα , VEGFR2 , FGFR1 , and Src , respectively.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Blood Disease | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Acute Lymphoblastic Leukemia | Products > Disease Areas > Chronic Myelogenous Leukemia | Products > Disease Areas > Pancreatic Ductal Adenocarcinoma | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > Src | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-12047
• CAS No.: 943319-70-8
• Molecular Formula: C29H27F3N6O
• Molecular Weight: 532.56
• Purity: 99.67%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.69 mM); Clear solution
• Availability: In-stock

Source

Original product source